Cargando…

Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Qingliang, Higasijima, Kouki, Wakabayashi, Rie, Tahara, Yoshiro, Kitaoka, Momoko, Obayashi, Hiroki, Hou, Yanting, Kamiya, Noriho, Goto, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920820/
https://www.ncbi.nlm.nih.gov/pubmed/31671640
http://dx.doi.org/10.3390/pharmaceutics11110563
_version_ 1783481020473933824
author Kong, Qingliang
Higasijima, Kouki
Wakabayashi, Rie
Tahara, Yoshiro
Kitaoka, Momoko
Obayashi, Hiroki
Hou, Yanting
Kamiya, Noriho
Goto, Masahiro
author_facet Kong, Qingliang
Higasijima, Kouki
Wakabayashi, Rie
Tahara, Yoshiro
Kitaoka, Momoko
Obayashi, Hiroki
Hou, Yanting
Kamiya, Noriho
Goto, Masahiro
author_sort Kong, Qingliang
collection PubMed
description Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.
format Online
Article
Text
id pubmed-6920820
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69208202019-12-24 Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy Kong, Qingliang Higasijima, Kouki Wakabayashi, Rie Tahara, Yoshiro Kitaoka, Momoko Obayashi, Hiroki Hou, Yanting Kamiya, Noriho Goto, Masahiro Pharmaceutics Article Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis. MDPI 2019-10-30 /pmc/articles/PMC6920820/ /pubmed/31671640 http://dx.doi.org/10.3390/pharmaceutics11110563 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kong, Qingliang
Higasijima, Kouki
Wakabayashi, Rie
Tahara, Yoshiro
Kitaoka, Momoko
Obayashi, Hiroki
Hou, Yanting
Kamiya, Noriho
Goto, Masahiro
Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy
title Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy
title_full Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy
title_fullStr Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy
title_full_unstemmed Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy
title_short Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy
title_sort transcutaneous delivery of immunomodulating pollen extract-galactomannan conjugate by solid-in-oil nanodispersions for pollinosis immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920820/
https://www.ncbi.nlm.nih.gov/pubmed/31671640
http://dx.doi.org/10.3390/pharmaceutics11110563
work_keys_str_mv AT kongqingliang transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT higasijimakouki transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT wakabayashirie transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT taharayoshiro transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT kitaokamomoko transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT obayashihiroki transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT houyanting transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT kamiyanoriho transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy
AT gotomasahiro transcutaneousdeliveryofimmunomodulatingpollenextractgalactomannanconjugatebysolidinoilnanodispersionsforpollinosisimmunotherapy